Document Detail


Fucoxanthin-rich seaweed extract suppresses body weight gain and improves lipid metabolism in high-fat-fed C57BL/6J mice.
MedLine Citation:
PMID:  20845386     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
An ethanol extract of fucoxanthin-rich seaweed was examined for its effectiveness as a nutraceutical for body fat-lowering agent and for an antiobese effect based on mode of actions in C57BL/6J mice. Animals were randomized to receive a semi-purified high-fat diet (20% dietary fat, 10% corn oil and 10% lard) supplemented with 0.2% conjugated linoleic acid (CLA) as the positive control, 1.43% or 5.72% fucoxanthin-rich seaweed ethanol extract (Fx-SEE), equivalent to 0.05% or 0.2% dietary fucoxanthin for six weeks. Results showed that supplementation with both doses of Fx-SEE significantly reduced body and abdominal white adipose tissue (WAT) weights, plasma and hepatic triglyceride (TG), and/or cholesterol concentrations compared to the high-fat control group. Activities of adipocytic fatty acid (FA) synthesis, hepatic FA and TG synthesis, and cholesterol-regulating enzyme were also lowered by Fx-SEE supplement. Concentrations of plasma high-density lipoprotein-cholesterol, fecal TG and cholesterol, as well as FA oxidation enzyme activity and UCP1 mRNA expression in epididymal WAT were significantly higher in the Fx-SEE groups than in the high-fat control group. CLA treatment reduced the body weight gain and plasma TG concentration. Overall, these results indicate that Fx-SEE affects the plasma and hepatic lipid profile, fecal lipids and body fat mass, and alters hepatic cholesterol metabolism, FA synthesis and lipid absorption.
Authors:
Seon-Min Jeon; Hye-Jin Kim; Myoung-Nam Woo; Mi-Kyung Lee; Young Chul Shin; Yong Bok Park; Myung-Sook Choi
Related Documents :
19147676 - Bexarotene induces dyslipidemia by increased very low-density lipoprotein production an...
8421086 - Differences in postprandial lipemia between patients with normal glucose tolerance and ...
2633106 - Lipidemic effects of a mild-term treatment with calcium heparin in vasculopathic subjects.
4370656 - Mechanisms for development of diabetic hypertriglyceridemia in streptozotocin-treated r...
2369116 - Invisible fats: sensory assessment of sugar/fat mixtures.
5947986 - Origin of milk cholesterol in the rat: dietary versus endogenous sources.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Biotechnology journal     Volume:  5     ISSN:  1860-7314     ISO Abbreviation:  Biotechnol J     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-16     Completed Date:  2010-12-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101265833     Medline TA:  Biotechnol J     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  961-9     Citation Subset:  IM    
Affiliation:
Department of Food Science and Nutrition, Kyungpook National University, Daegu, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Obesity Agents / pharmacology
Body Weight
Cholesterol / blood
Dietary Fats / administration & dosage,  metabolism
Dietary Supplements
Lipid Metabolism*
Lipids / blood
Male
Mice
Mice, Inbred C57BL
Obesity / metabolism,  therapy
Plant Extracts / isolation & purification*,  pharmacology
Seaweed / metabolism*
Weight Gain
Xanthophylls / pharmacology*
Chemical
Reg. No./Substance:
0/Anti-Obesity Agents; 0/Dietary Fats; 0/Lipids; 0/Plant Extracts; 0/Xanthophylls; 3351-86-8/fucoxanthin; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hepatoprotective effect of oleuropein in mice: mechanisms uncovered by gene expression profiling.
Next Document:  Large scale purification of linear plasmid DNA for efficient high throughput cloning.